The Lilly Cares® Foundation Patient Assistance Program ("Lilly Cares") Prescription FAX Form Taltz® (ixekizumab) injection for subcutaneous use

Patient Information:			
Patient Name:		Date of Birth:	Today's Date:
Address:			
	State:	Zin Code:	Phone:
	ent address above, No P.O. Box or thir		1 110116.
	cin address above, No 110. Box of this	a-party vendor).	
City:	State:		Zip Code:
Drug Allergies:			
Other Medications:			
Rx: I authorize Lilly Cares to act on my be select Fortrea Specialty Pharmacy (NPI		s prescription to the appropriate	e pharmacy. To submit an electronic prescription, please
Faltz [®] Injection Device (choose one Please indicate ADULT patient's t			
Taltz [®] is indicated for the treatment	t of moderate to severe plaque psoria	asis in adult patients who are	candidates for systemic therapy or phototherapy.
For adult patients with psoriatic art	thritis and coexistent moderate to se	vere plaque psoriasis, follow	the dosing for plaque psoriasis.
Starting Dose: □ 2	x 80 mg (160 mg) subcutaneous injecti	ons	
Next Two Induction Doses:	x 80 mg subcutaneous injection every 2	2 weeks (weeks 2-4). Quantity to	be dispensed is 2 doses.
Remaining Induction Doses: 🗆 1	x 80 mg subcutaneous injection every 2	weeks (weeks 6-12). Quantity	to be dispensed is 4 doses.
Maintenance Dose: □ 1	x 80 mg subcutaneous injection every 4	weeks (after week 12)	
	OR		
follow the dosing for plaque pso 2. Taltz [®] is indicated for adult pation Starting Dose: □ 2 x 80 mg (160	e arthritis and coexistent moderate to oriasis. ents with active ankylosing spondyli		Taltz® is indicated for adult patients with active non-radiographic axial spondyloarthritis with objective signs of inflammation. Dose: □ 1 x 80 mg subcutaneous injection every 4 weeks
Disease in disease DEDIATRIO metion	We to store the allege floor also also as	- :1.	
Please indicate PEDIATRIC patien Taltz® is indicated for the treatmer systemic therapy or phototherapy	nt of pediatric patients 6 years of ag		evere plaque psoriasis who are candidates for
B 24 - B - 1 - 1 - B - 1 - 1 - 1 - 1	D	D	
Pediatric Psoriasis Patient Weight If >50 kg (110 lbs)	Device Type	Dosing	/400 t-t-D bbt
11 > 30 kg (110 lbs)	□ 80 mg/mL Prefilled syringe □ 80 mg/mL Autoinjector		(160 mg total) by subcutaneous injection on Day 1 O mg by subcutaneous injection every 4 weeks (thereafter)
If 25 kg (55 lbs) or ≤50 kg (110 lbs)	□ 80 mg/mL Prefilled syringe □ 40 mg/0.5 mL Prefilled syringe	□ Starting Dose: 1 x 80 mg by subcutaneous injection on Day 1 □ Maintenance Dose: 1 x 40 mg by subcutaneous injection every 4 weeks (thereafter)	
If <25 kg (55 lbs)	□ 40 mg/0.5 mL Prefilled syringe □ 20 mg/0.25 mL Prefilled syringe	□ Starting Dose: 1 x 40 mg	by subcutaneous injection on Day 1 O mg by subcutaneous injection every 4 weeks (thereafter)
For pediatric patients ≤50 kg (110 lbs), subcutaneous injection technique.	Taltz® must be administered by a heal	lthcare professional or a caregi	ver who has received training and demonstrated proper
Quantity to be Dispensed:	4 months (max) □ 3 mon	nths □ 2 month	ns 🗆 1 month
Refills: #(up to c	one year of treatment)		
Your state may require that prescriptions	follow certain content requirements or a prescribers in the states in which you	, , ,	g below you certify that you are abiding by laws y Cares to act on my behalf for the limited purposes
Cianatura			
Signature:	as written	Subs	titution/brand exchange permitted
•			<u> </u>
Rubber stamps, signature by other office	,	· ·	·
			FAX:
State License Number and State:			Phone:
Prescriber Office/Clinic Name and Shippi	ng Address (No PO Box):		

IMPORTANT: This information is intended for the use of the person or entity to which it is addressed and may contain information that is confidential, the disclosure of which is governed by applicable law. If the reader of this information is not the intended recipient, or the authorized agent or individual responsible to deliver it to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this information is STRICTLY PROHIBITED. If you received this document in error, please notify us immediately and destroy the related document.

Lilly Cares Foundation Patient Assistance Program

PO Box 501847 | San Diego, CA 92150 | Phone: 1-800-545-6962 | Fax: 1-844-431-6650 | www.LillyCares.com